Bayer has announced strategic collaborations with the Emirates ENT Society and the Emirates Pharmacists Society, marking a significant step forward in addressing the rising burden of allergic rhinitis across the UAE. The announcement was made during a regional allergy awareness media roundtable held in Dubai, aligning with the upcoming launch of ClariSpray, Bayer’s latest innovation in allergy relief.
Allergic rhinitis affects up to 45% of the population in the region, significantly impacting daily life, work productivity, and overall well-being. Bayer’s renewed focus on allergy care combines scientific innovation with a deep commitment to education and awareness, ensuring that both patients and healthcare professionals are better equipped to manage this widespread condition.
Speaking on the partnership, Dr. Mohammed Ahmed Abdulla Al Hammadi, Vice President of the Emirates ENT Society, emphasized the importance of collaborative efforts:
“Collaboration between the medical sector and specialized partners is a fundamental pillar for advancing healthcare. This partnership with Bayer provides an opportunity to merge clinical expertise with innovative solutions, ultimately enhancing patient outcomes across the region.”
Dr. Abdulla Al Kindi, Head of the Emirates Pharmacists Society, highlighted the importance of pharmacist-led care in allergy management:
“To better serve allergic rhinitis patients, our society sees this partnership as vital. Working together with industry leaders enables us to respond more effectively to patient needs and support improved quality of life.”
ClariSpray, set to launch soon, is Bayer’s new intranasal spray designed to deliver fast, effective relief from allergic rhinitis symptoms. It reflects the company’s long-standing focus on patient-centric, evidence-based solutions.
Dr. Mohammad Galal, Vice President and Head of Middle East & Pakistan at Bayer Consumer Health, said:
“Our goal is to empower individuals to take control of their health. The launch of ClariSpray, supported by these meaningful partnerships, demonstrates our commitment to tackling allergic rhinitis across the GCC. We aim to elevate awareness, improve access, and deliver impactful solutions to patients.”
This collaboration also seeks to deepen the understanding of regional allergy patterns, improve access to education and care, and enhance the capacity of healthcare professionals through ongoing training and engagement.
